Congress caps insulin copays at $35, funds uninsured access programs

What it does

This bill caps insulin copays at $35 per 30-day supply for insured patients starting in 2028, with the cap potentially lowering to 25% of the negotiated price if that is less. It also funds a resource center and hotline to help uninsured individuals find manufacturer assistance programs, directs a study on uninsured insulin users, and expedites FDA approval of competing biosimilar insulins to increase competition and lower prices.

Why we flagged it

The bill's operative mechanism is a copay cap for insured patients ($35 or 25% of negotiated price) combined with biosimilar competition acceleration and uninsured patient support. The primary civic effect is reducing out-of-pocket insulin costs across both insured and uninsured populations.

What the text implies

• The copay cap applies only to 'selected insulin products' (at least one of each type/dosage/delivery form chosen by the plan), not all insulins—plans retain discretion to impose higher cost-sharing on non-selected products, potentially steering patients toward cheaper options.
• Biosimilar expedited review may accelerate market entry of competing insulins, but the bill does not guarantee price reductions for uninsured patients; it relies on market competition and manufacturer assistance programs, which are voluntary.
• The $2M annual grant for the uninsured resource center (2027–2032) is modest relative to the scale of uninsured insulin users; effectiveness depends on uptake and manufacturer participation in assistance programs.
• Out-of-network insulin delivery is explicitly carved out—plans may impose higher cost-sharing for out-of-network providers, potentially creating access gaps in rural or underserved areas.
• The bill exempts selected insulin copay relief from counting toward a plan's actuarial value, preventing insurers from claiming the copay cap increases plan value and thus premium costs—a technical provision that protects affordability but is invisible to consumers.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Insured patients gain immediate, concrete copay relief (capped at $35 or 25% of negotiated price). Uninsured patients benefit from increased biosimilar competition and a federally-funded resource center connecting them to manufacturer assistance programs. The bill does not restrict coverage of non-selected insulins or impose new burdens on patients.

Who stands to gain

• Insured patients (reduced copays)
• Biosimilar manufacturers (expedited FDA review pathway)
• Uninsured patients (via manufacturer assistance programs and resource center)

Named in the bill

Department of Health and Human Services, FDA (Food and Drug Administration), Insulin manufacturers, Biosimilar manufacturers, Health insurance issuers, Group health plans, Pharmacy benefit managers, Federally-qualified health centers, Community pharmacies

Where it stands

19 cosponsors: 16 Democrats, 3 Republicans.

• Sep 2, 2026 — Introduced · Congress.gov: “Introduced in House”
• Sep 2, 2026 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.